Vancomycin Dominates as First-Line Defense Against MRSA Infections

Vancomycin, which has experienced increased usage over the past five years, continues to dominate as a first-line treatment of MRSA infections, according to a Decision Resources and Arlington Medical Resources news release.

AMR analyzed survey data from infectious disease specialists and internists as well as hospital patient-level medical data. Sixty to 76 percent of surveyed infectious disease specialists indicated that they use vancomycin as first-line treatment for bloodstream infections, complicated skin and skin structure infections and hospital-acquired pneumonia suspected to or confirmed to involve MRSA.

Results also showed surveyed infectious disease specialists consider sepsis and prosthetic joint infections to be the most difficult-to-treat indications needing novel anti-MRSA therapies. Additionally, patient-level audit data of drug costs and usage reveal high antibiotic costs for sepsis and prosthetic joint infections due to long treatment duration and use of premium-priced antibiotics.

Read the AMR news release about MRSA treatments.

Related Articles About MRSA:
Study: Hospital Employees Display Positive Perceptions Toward MRSA Screening Mandates
Study: Antibiotic Linezolid an Effective Treatment for MRSA Infection
Study: Healthcare Workers May Blame External Factors for MRSA Infections

Copyright © 2024 Becker's Healthcare. All Rights Reserved. Privacy Policy. Cookie Policy. Linking and Reprinting Policy.

 

Articles We Think You'll Like

 

Featured Whitepapers

Featured Webinars